NCT02480335View on ClinicalTrials.gov

The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 26, 2015

Primary Completion Date

July 30, 2018

Study Completion Date

July 30, 2018

Conditions
Scleroderma, Systemic
Interventions
DRUG

bosentan

62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.

Trial Locations (1)

9700 RB

University Medical Center Groningen, Groningen

Sponsors

Collaborators (1)

Actelion
All Listed Sponsors
collaborator

Actelion

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT02480335 - The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis | Biotech Hunter | Biotech Hunter